Prouty Megan E, Fischer Ryan, Liu Deede
University of Kansas Medical Center, Department of Dermatology, Kansas City, KS.
Dermatol Online J. 2016 Oct 15;22(10):13030/qt4wp1g44b.
Hyperhidrosis, or abnormally increased sweating, is a condition that may have a primary or secondary cause. Usually medication- induced secondary hyperhidrosis manifests with generalized, rather than focal sweating. We report a 32-year-old woman with a history of palmoplantar hyperhidrosis for 15 years who presented for treatment and was prescribed oral glycopyrrolate. One month later, the palmoplantar hyperhidrosis had resolved, but she developed new persistent craniofacial sweating. After an unsuccessful trial of clonidine, oxybutynin resolved the craniofacial hyperhidrosis. To our knowledge, this is the first case of compensatory hyperhidrosis secondary to glycopyrrolate reported in the literature. The case highlights the importance of reviewing medication changes that correlate with new onset or changing hyperhidrosis. It also demonstrates a rare drug adverse effect with successful treatment.
多汗症,即异常多汗,是一种可能有原发性或继发性病因的病症。通常,药物引起的继发性多汗症表现为全身性出汗,而非局部出汗。我们报告一例32岁女性,有手掌足底多汗症病史15年,前来接受治疗,服用了口服格隆溴铵。一个月后,手掌足底多汗症消失,但她出现了新的持续性头面部出汗。可乐定试验失败后,奥昔布宁解决了头面部多汗症。据我们所知,这是文献中报道的首例格隆溴铵继发的代偿性多汗症病例。该病例突出了审查与新发或变化的多汗症相关的药物变化的重要性。它还展示了一种罕见的药物不良反应及成功的治疗方法。